Citadel Advisors
UBX

Citadel Advisors’s Unity Biotechnology UBX Stock Holding History

Citadel Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42,300
Closed -$16.1K – 14163
2025
Q2 		$16.1K Buy
42,300
+3,400
+9% +$2.91K ﹤0.01% 12148
2025
Q1 		$40.5K Buy
+38,900
New +$70.3K ﹤0.01% 12528
2024
Q4 		– Sell
-39,400
Closed -$57.9K – 15420
2024
Q3 		$57.9K Buy
39,400
+25,900
+192% +$38K ﹤0.01% 11746
2024
Q2 		$18.2K Buy
13,500
+8,900
+193% +$13.5K ﹤0.01% 12723
2024
Q1 		$7.54K Sell
4,600
-8,250
-64% -$14.3K ﹤0.01% 13610
2023
Q4 		$24.8K Sell
12,850
-34,600
-73% -$64.3K ﹤0.01% 12441
2023
Q3 		$114K Sell
47,450
-2,900
-6% -$7.68K ﹤0.01% 10724
2023
Q2 		$128K Buy
50,350
+28,400
+129% +$75K ﹤0.01% 10561
2023
Q1 		$35.8K Buy
21,950
+12,560
+134% +$50.3K ﹤0.01% 12564
2022
Q4 		$25.7K Buy
9,390
+2,840
+43% +$8.25K ﹤0.01% 12917
2022
Q3 		$26K Sell
6,550
-17,740
-73% -$112K ﹤0.01% 11971
2022
Q2 		$137K Buy
24,290
+14,020
+137% +$117K ﹤0.01% 11076
2022
Q1 		$115K Buy
10,270
+9,120
+793% +$102K ﹤0.01% 12133
2021
Q4 		$17K Sell
1,150
-580
-34% -$12.7K ﹤0.01% 13606
2021
Q3 		$52K Sell
1,730
-780
-31% -$27.5K ﹤0.01% 13354
2021
Q2 		$116K Buy
+2,510
New +$121K ﹤0.01% 12779
2021
Q1 		– Sell
-6,560
Closed -$344K – 13729
2020
Q4 		$344K Buy
6,560
+860
+15% +$41.5K ﹤0.01% 8830
2020
Q3 		$197K Buy
+5,700
New +$361K ﹤0.01% 8814

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Citadel Advisors's UBX Position: Q4 2024 in Review

Citadel Advisors sold out of Unity Biotechnology (UBX) in Q4 2024, closing a stake of 69,210 shares — an estimated $102K sold.

Citadel Advisors first reported a position in UBX in Q2 2018 and held it in 23 quarters. The position peaked at $2.64M in Q4 2019. 37 funds tracked by Wall St. Rank hold UBX as of Q4 2024.

  • Citadel Advisors reported no remaining Unity Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 69,210 Unity Biotechnology shares in Q4 2024, an estimated $102K.
  • Citadel Advisors first reported a position in Unity Biotechnology in Q2 2018 and held it in 23 quarters.
  • Citadel Advisors's Unity Biotechnology position peaked at $2.64M in Q4 2019.
  • 37 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.